Revumenib, cytarabine, daunorubicin, idarubicin clinical trials

Phase III study of revumenib in combination with intensive chemotherapy in newly diagnosed NPM1-mutated AML

This study looks at adding a new drug, revumenib, to standard chemotherapy for a type of blood cancer called AML when it has a specific gene change (NPM1 mutation). It aims to see if this new combination works better to treat the cancer.